MBX Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	45.21	75.29	49.35	30.52	30.52
Short-Term Investments	394.76	298.42	212.8	50.15	50.15
Cash & Short-Term Investments	439.98	373.71	262.15	80.68	80.68
Cash Growth	82.73%	42.55%	224.94%	-	-
Other Current Assets	8.56	7.83	5.14	2.79	2.79
Total Current Assets	448.54	381.54	267.29	83.47	83.47
Net Property, Plant & Equipment	3.59	3.22	1.2	0.67	0.67
Other Long-Term Assets	0.58	0.38	0.05	0.05	0.05
Total Assets	452.7	385.14	268.54	84.18	84.18
Accounts Payable	6.97	2.98	5.34	1.39	1.39
Accrued Expenses	7.42	12.35	5.55	2.38	2.38
Current Portion of Leases	0.18	0.17	0.17	0.15	0.15
Total Current Liabilities	14.57	15.5	11.05	3.93	3.93
Long-Term Leases	0.38	0.42	-	0.17	0.17
Other Long-Term Liabilities	0	0	0.04	0.19	0.19
Total Long-Term Liabilities	0.38	0.43	0.04	0.37	0.37
Total Liabilities	14.95	15.92	11.09	4.29	4.29
Common Stock	0.01	0.01	0.01	0	0
Additional Paid-in Capital	686.35	593.41	394.89	3.05	3.05
Accumulated Other Comprehensive Income	-0.61	0.29	0.06	0.06	0.06
Retained Earnings	-247.99	-224.48	-137.51	-75.58	-75.58
Minority Interest	-	-	-	152.36	152.36
Shareholders' Equity	437.76	369.22	257.44	-72.47	-72.47
Total Liabilities & Equity	452.7	385.14	268.54	84.18	84.18
Total Debt	0.56	0.6	0.17	0.32	0.32
Net Cash (Debt)	439.42	373.11	261.98	80.35	80.35
Net Cash Growth	17.77%	42.42%	226.04%	-	-
Net Cash Per Share	11.05	10.22	24.61	78.87	120.47
Book Value	437.76	369.22	257.44	-72.47	-72.47
Book Value Per Share	11.01	10.11	24.19	-71.13	-108.64
Tangible Book Value	437.76	369.22	257.44	-72.47	-72.47
Tangible Book Value Per Share	11.01	10.11	24.19	-71.13	-108.64

SEC Filings: 10-K · 10-Q